Vandoeuvre-lès-Nancy - CRLCC
Welcome,         Profile    Billing    Logout  
 21 Trials 
47 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CLEMENT-DUCHENE, Christelle
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Active, not recruiting
3
500
Europe
Carboplatin, Paclitaxel, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
12/24
12/26
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy MAintenance Duration Trial for Stage IV Lung Cancer Patients with Disease Control After Chemo-immunotherapy Induction

Recruiting
2/3
1360
Europe
Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization
Intergroupe Francophone de Cancerologie Thoracique, IFCT
Metastatic NSCLC
01/25
06/29
SAVIMMUNE, NCT04108026 / 2018-004742-42: Immunotherapy in Patient with Poor General Condition

Active, not recruiting
2
50
Europe
Durvalumab
Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca
Non-small Cell Lung Cancer Stage IV
11/23
10/25
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib with Binimetinib in BRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
12/24
03/26
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting
2
110
Europe
Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, ALK Gene Mutation
04/25
10/28
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)

Recruiting
2
67
Europe
Carboplatin + Paclitaxel + Durvalumab
Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer Extensive Stage
02/26
02/28
RADIO-RYTHMIC, NCT04731610: Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma

Recruiting
N/A
314
Europe
Radiotherapy, Surveillance after resection
Institut Curie
Thymoma Malignant Recurrent
02/25
03/29
NCT04720339: Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.

Recruiting
N/A
250
Europe
Molecular monitoring by quantification of cell-free DNA
University Hospital, Strasbourg, France
NSCLC, IMMUNOTHERAPY, QUANTIFICATION OF CELL-FREE DNA
05/25
10/27
MORO-SIBILOT, Denis
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Active, not recruiting
3
500
Europe
Carboplatin, Paclitaxel, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
12/24
12/26
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting
3
756
Europe, US, RoW
Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
07/27
07/29
NCT05027867 / 2021-001530-19: KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Terminated
2
3
Europe, US, RoW
KRT-232, navtemadlin
Kartos Therapeutics, Inc.
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
08/22
08/22
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Completed
2
57
Europe
Osimertinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation
03/23
12/24
SAVIMMUNE, NCT04108026 / 2018-004742-42: Immunotherapy in Patient with Poor General Condition

Active, not recruiting
2
50
Europe
Durvalumab
Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca
Non-small Cell Lung Cancer Stage IV
11/23
10/25
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer

Active, not recruiting
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
01/25
01/25
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib with Binimetinib in BRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
12/24
03/26
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS)

Recruiting
2
84
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
03/25
01/26
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting
2
110
Europe
Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, ALK Gene Mutation
04/25
10/28
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

Active, not recruiting
2
156
Europe
Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer
09/25
06/26
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)

Recruiting
2
67
Europe
Carboplatin + Paclitaxel + Durvalumab
Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer Extensive Stage
02/26
02/28
PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting
1/2
73
Europe
PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed
PDC*line Pharma SAS
Non Small Cell Lung Cancer
07/24
12/25
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
SHIELD-1, NCT03993873: Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Active, not recruiting
1
95
Europe, US, RoW
elzovantinib (TPX-0022)
Turning Point Therapeutics, Inc.
Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
01/24
03/26
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Terminated
1
28
Europe, RoW
BBP-398, sotorasib
Navire Pharma Inc., a BridgeBio company, Amgen
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
08/24
08/24
LIBIL, NCT02511288: LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer

Recruiting
N/A
900
Europe
Centre Leon Berard
Carcinoma, Non-Small-Cell Lung
03/26
12/26
COURAUD, Sébastien
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Active, not recruiting
3
500
Europe
Carboplatin, Paclitaxel, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
12/24
12/26
DICOV, NCT05563168 / 2021-004160-94: Study Evaluating Diltiazem in Combination With Standard Treatment in the Management of Patients Hospitalized With COVID-19 Pneumonia

Withdrawn
2b
250
Europe
DILTIAZEM TEVA 60 mg or placebo
Hospices Civils de Lyon, Signia Therapeutics
COVID-19
10/24
12/24
NCT05027867 / 2021-001530-19: KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Terminated
2
3
Europe, US, RoW
KRT-232, navtemadlin
Kartos Therapeutics, Inc.
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
08/22
08/22
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Completed
2
57
Europe
Osimertinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation
03/23
12/24
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib with Binimetinib in BRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
12/24
03/26
FIRST-NEC, NCT06393816: (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Recruiting
2
80
Europe, RoW
Durvalumab with etoposide and Carboplatin/Cisplatin, MEDI4736
Centre Leon Berard, Groupe Français de Pneumo-Cancérologie
Large Cell Neuroendocrine Carcinoma of the Lung
09/28
09/29
SPORADIC, NCT06656598: Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer

Not yet recruiting
2
152
Europe
Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance)
Intergroupe Francophone de Cancerologie Thoracique
Stage III NSCLC
09/28
01/32
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

Active, not recruiting
2
156
Europe
Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer
09/25
06/26
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)

Recruiting
2
67
Europe
Carboplatin + Paclitaxel + Durvalumab
Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer Extensive Stage
02/26
02/28
HPI-COVID-19, NCT04376476: Host-pathogen Interactions During SARS-CoV-2 Infection

Completed
N/A
140
Europe
Blood sample, Low or upper respiratory tract sample, Stool collection or fecal swab, phone call
Hospices Civils de Lyon
Infection, Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2
05/22
05/22
FatCovid-19, NCT04363606: Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability

Terminated
N/A
65
Europe
Questionnaires, blood test, Maximal effort test, actigraphy, Neuromuscular evaluation, stool analysis, food diary
Centre Hospitalier Universitaire de Saint Etienne, University of Saint-Etienne, Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques
Chronic Fatigue Syndrome, Intensive Care Unit, Muscle
07/21
08/21
LUTON, NCT04957602: Evaluation of a Novel Microfluidic Device to Purify Metastatic Lung Cancer Patients CTC (Circulating Tumoral Cells)

Terminated
N/A
6
Europe
Blood collection
Hospices Civils de Lyon
Non Small Cell Lung Cancer
09/22
09/22
DEEP-Lung-IV, NCT04994795: Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

Active, not recruiting
N/A
4000
Europe, Canada, US, RoW
Predictive models (data collection)
Sophia Genetics SAS
Non-small Cell Lung Cancer Metastatic
12/24
02/25
MADMAS, NCT05091190: Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers

Recruiting
N/A
60
Europe
Blood draws
Hospices Civils de Lyon
Metastatic NSCLC, Metastatic Head and Neck Cancer
10/28
10/28
ILYAD, NCT05452200: Lung Cancer Screening Implementation Among Employees at Lyon Hospital

Recruiting
N/A
600
Europe
Solicitation for lung cancer screening, added exams to the usual lung cancer screening
Hospices Civils de Lyon
Lung Cancer
09/24
09/24
INOVOLINE, NCT05472532: Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)

Recruiting
N/A
132
Europe
Patient sampling.
Hospices Civils de Lyon
Cancer Metastatic, Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Gastric Cancer
12/24
12/24
CIRCULAR, NCT04912687: Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

Recruiting
N/A
580
Europe
EGFR gene mutation analysis on liquid biopsy
Institut Bergonié, AstraZeneca
Non Small Cell Lung Cancer, Advanced Solid Tumor
01/25
01/26
SyPoCo, NCT05805566: Retrospective and Prospective Cohort of Patients Entering the Multidisciplinary Management of Post-Covid Syndromes

Recruiting
N/A
750
Europe
Blood collection
Hospices Civils de Lyon
Post-Covid Syndrome
04/29
04/29
MONITOR, NCT04605146: Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy

Recruiting
N/A
100
Europe
Tele-monitoring
Hospices Civils de Lyon
Melanoma, Lung Cancer, Renal Cancer
11/28
11/28
IMMUCARE-BASE, NCT03989323: A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE

Recruiting
N/A
2000
Europe
Estimation of the incidence of the irAE
Hospices Civils de Lyon
Cancer
07/29
07/29
ULYSSE, NCT05267041: Joint Thoracic Oncology Research Unit of LYon: Lung CancerS DatabaSE

Recruiting
N/A
4000
Europe
Quality of life questionnaire, Blood sample
Hospices Civils de Lyon
Lung Cancer
05/32
05/42
SMALLHAN, NCT05523583: Assessment of Tobacco Smoking and Alcohol Drinking and Treatment Outcomes Among Patients With Lung or Head and Neck Cancer

Recruiting
N/A
165
Europe
questionnaire, Tabacco and alcohol questionnaires
Hospices Civils de Lyon, International Agency for Research on Cancer
Lung or Head and Neck Cancer
10/25
10/25

Download Options